长沙晚报掌上长沙2月19日讯（全媒体记者 徐媛）近日，湖南省医保局印发《湖南省城乡居民高血压糖 尿病门诊用药范围及医保支付标准（2026版）》，结合国家医保药品目录（2025年）调整情况，进一步 优化湖南省城乡居民高血压、糖尿病（以下简称"两病"）门诊用药保障政策，建立科学规范的用药范围 和支付标准动态调整机制，切实减轻参保患者用药负担，保障用药需求。 用药范围进一步拓宽，两类核心药品全覆盖 此次政策调整以2025年版"两病"门诊用药范围及支付标准为基础，严格对照《国家基本医疗保险、工伤 保险和生育保险药品目录（2025年）》，将两类关键药品全部纳入"两病"门诊用药范围。 其中，对西药部分、协议期内谈判药品两个部分中高血压用药（药品分类代码XC02抗高血压药、XC03 利尿剂、XC07/XC07Aβ-受体阻滞剂、XC08钙通道阻滞剂、XC09作用于肾素-血管紧张素系统的药 物）、糖尿病用药（药品分类代码XA10），全部纳入两病用药范围，进一步拓宽了参保患者的用药选 择。 动态调整"两病"门诊用药范围，持续优化服务 在医保支付标准方面，湖南省严格按照国家相关规定，对国家谈判及集采范围内的"两病"药品支付标准 进 ...

Core Viewpoint - The article highlights significant announcements in the stock market from Sunday to Thursday, focusing on various corporate actions such as suspensions, share buybacks, investment wins, acquisitions, earnings reports, and stock unlocks, aiming to help investors identify potential investment opportunities and risks in advance [1] Group 1 - The company has formed a strategic partnership with Zhiyuan Robotics and has secured hardware orders from domestic and international humanoid robot clients [1] - The company is developing six innovative drugs, including those for hypertension [1] - The company has entered the supply chain of leading humanoid robot manufacturers, engaging in sectors such as controllable nuclear fusion, low-altitude economy, and new energy vehicles [1]